Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.39
$24.55
$19.69
▼
$29.76
$5.08B0.811.68 million shs643,303 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$254.31
-0.5%		$246.76
$186.05
▼
$282.15
$15.82B0.39689,388 shs204,966 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$84.70
+0.0%		$76.07
$46.81
▼
$93.42
$16.51B0.962.99 million shs1.48 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$51.61
-2.6%		$54.22
$33.76
▼
$57.57
$13.00B0.442.72 million shs845,576 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+0.62%+14.76%+12.09%+35.31%+19.47%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.08%+5.00%-5.48%+7.56%+33.49%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.22%+5.89%-1.42%+28.39%+81.77%
Exelixis, Inc. stock logo
EXEL
Exelixis
-2.05%-3.81%-6.27%+7.08%+40.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.39
$24.55
$19.69
▼
$29.76
$5.08B0.811.68 million shs643,303 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$254.31
-0.5%		$246.76
$186.05
▼
$282.15
$15.82B0.39689,388 shs204,966 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$84.70
+0.0%		$76.07
$46.81
▼
$93.42
$16.51B0.962.99 million shs1.48 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$51.61
-2.6%		$54.22
$33.76
▼
$57.57
$13.00B0.442.72 million shs845,576 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+0.62%+14.76%+12.09%+35.31%+19.47%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.08%+5.00%-5.48%+7.56%+33.49%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.22%+5.89%-1.42%+28.39%+81.77%
Exelixis, Inc. stock logo
EXEL
Exelixis
-2.05%-3.81%-6.27%+7.08%+40.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.82
Moderate Buy$33.3113.32% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.06
Buy$296.1216.44% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$99.5317.50% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.26
Hold$49.79-3.53% Downside

Current Analyst Ratings Breakdown

Latest ACAD, BBIO, ASND, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$110.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$101.00 ➝ $104.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$98.00 ➝ $97.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$95.00 ➝ $110.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$98.00 ➝ $102.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$111.00 ➝ $115.00
8/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$27.00
8/10/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$35.00 ➝ $39.00
8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$56.00 ➝ $52.00
8/6/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$52.00
(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.73$0.89 per share32.93$7.25 per share4.05
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$865.78M18.32N/AN/A($2.97) per share-85.63
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M32.98N/AN/A($10.77) per share-7.86
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B5.59$2.89 per share17.86$8.06 per share6.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2213.2729.6923.7633.42%9.03%6.79%N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6729.2622.06N/A57.87%N/A-8.37%8/13/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A1,210.03N/A-124.42%N/A-65.81%N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1816.2713.951.6335.33%42.17%31.76%N/A

Latest ACAD, BBIO, ASND, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71N/AN/AN/A$376.75 millionN/A
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510172.31 million127.16 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077251.35 million244.82 millionOptionable

Recent News About These Companies

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
August 10 at 6:19 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/exelixis-investigation-notice-levi--korsinsky-notifies-investors-of-pending-investigation-into-exelixis-exel-302847550.html
Bank of America Corp DE Sells 578,181 Shares of Exelixis, Inc. $EXEL
August 10 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-sells-578181-shares-of-exelixis-inc-exel-2026-08-10/
Exelixis, Inc. $EXEL Shares Acquired by Assenagon Asset Management S.A.
August 10 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-acquired-by-assenagon-asset-management-sa-2026-08-10/
Why this top-ranked IBD 50 stock just tumbled on its earnings
August 8 at 5:44 PM  |  msn.comhttps://www.msn.com/en-us/money/topstocks/why-this-top-ranked-ibd-50-stock-just-tumbled-on-its-earnings/ar-AA29tKeH
Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL
August 8 at 3:06 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-sells-121348-shares-of-exelixis-inc-exel-2026-08-08/
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts
August 8 at 3:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30948170
Exelixis (NASDAQ:EXEL) Rating Lowered to "Buy" at Wall Street Zen
August 8 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30948012
Exelixis (NASDAQ:EXEL) Lowered to "Buy" Rating by Wall Street Zen
August 8 at 1:53 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/exelixis-nasdaqexel-lowered-to-buy-rating-by-wall-street-zen-2026-08-08/
What is Zacks Research's Estimate for Exelixis Q3 Earnings?
August 8 at 1:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947372
Exelixis Earnings Call: Cabo Strength, Zanza Awaited
August 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exelixis-earnings-call-cabo-strength-zanza-awaited?utm_source=marketbeat.com&utm_medium=referral
Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-boosts-holdings-in-exelixis-inc-exel-2026-08-07/
Exelixis (NASDAQ:EXEL) Downgraded by Leerink Partners to "Market Perform"
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30946975
Exelixis (NASDAQ:EXEL) Price Target Raised to $51.00 at Stifel Nicolaus
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30946532
What is Zacks Research's Estimate for Exelixis Q4 Earnings?
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945546
Exelixis (NASDAQ:EXEL) Rating Lowered to "Market Perform" at Leerink Partners
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/exelixis-nasdaqexel-rating-lowered-to-market-perform-at-leerink-partners-2026-08-06/
Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exelixis-targets-residual-colorectal-cancer-with-new-phase-3-trial?utm_source=marketbeat.com&utm_medium=referral
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970171/exel-tops-q2-earnings-estimates-misses-on-sales-lowers-26-view?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970171
Stifel Nicolaus Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/stifel-nicolaus-issues-positive-forecast-for-exelixis-nasdaqexel-stock-price-2026-08-06/
Exelixis, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931775-exelixis-inc-2026-q2-results-earnings-call-presentation
Zacks Research Predicts Exelixis' Q3 Earnings (NASDAQ:EXEL)
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zacks-research-predicts-exelixis-q3-earnings-nasdaqexel-2026-08-06/
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/exelixis-buy-rating-reaffirmed-on-cabozantinib-resilience-cost-discipline-and-zanzalintinib-upside-despite-near-term-net-guidance-cut-ratings-news?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
A gloved hand holds a white capsule pill in a pharmaceutical laboratory setting.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
By Jeffrey Neal Johnson | July 13, 2026
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.38 -0.01 (-0.03%)
As of 02:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$254.07 -1.55 (-0.61%)
As of 02:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$84.71 +0.04 (+0.05%)
As of 02:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$51.61 -1.35 (-2.55%)
As of 02:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas